Evidence map›Paper›PMID 38861286›Full record

ArticleFuture oncology (London, England)2024

Regorafenib in patients with metastatic colorectal cancer in Spain: from clinical trials to real-world evidence.

Andres Cervantes, Josep Tabernero, Rocio Garcia-Carbonero, Javier Sastre, Jaime Feliu, Carmen Guillén-Ponce, Beatriz García Paredes, Alberto Carral, Jorge Muñoz

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future oncology (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Andres CervantesMedical Oncology Department, Biomedical Research Institute INCLIVA, Hospital Clínico de Valencia, Universidad de Valencia, Valencia, Spain.
Josep TaberneroMedical Oncology Department, Vall d'Hebron Hospital Campus and Institute of Oncology (VHIO), UVic-UCC, IOB-Quiron, Barcelona, Spain.
Rocio Garcia-CarboneroMedical Oncology Department, Hospital Universitario 12 de Octubre, Imas12, UCM, CIBERONC, Madrid, Spain.
Javier SastreMedical Oncology Department, Hospital Clínico San Carlos, Madrid, Spain.
Jaime FeliuMedical Oncology Department, Hospital Universitario La Paz, IDIPAZ, CIBERONC, Cátedra UAM-AMGEN, Madrid, Spain.
Carmen Guillén-PonceMedical Oncology Department, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain.
Beatriz García ParedesMedical Oncology Department, Hospital Clínico San Carlos, Madrid, Spain.
Alberto CarralMedical Oncology Department, Hospital Universitario Lucus Augusti, Lugo, Spain.
Jorge MuñozMedical Oncology Department, Hospital San Pedro de Alcántara, Cáceres, Spain.

Funding

Bayer HealthCare
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Colorectal NeoplasmsPhenylurea CompoundsPyridinesAdultAgedAged, 80 and overAntineoplastic AgentsClinical Trials as TopicFemaleHumansMaleMiddle AgedNeoplasm MetastasisSpainTreatment OutcomeAntineoplastic AgentsPhenylurea CompoundsPyridinesregorafenibclinical trialevolutionmetastatic colorectal cancerreal-world evidenceregorafenibSpain

Identifiers

PMID38861286
PMCPMC11385448

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.